Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced a coverage agreement with a second major group purchasing organization, effective June 1, 2026, expanding access to its fibromyalgia treatment TONMYA to an additional 17 million U.S. commercial lives. This brings total commercial coverage to approximately 52 million lives, representing about 29% of the estimated 177 million commercially insured individuals in the United States.
TONMYA is also now available through Medicaid programs covering approximately 75 million lives, while discussions with Medicare continue. The expansion follows an earlier agreement in May that provided access to roughly 35 million commercial lives. TONMYA, a non-opioid analgesic designed for daily bedtime administration and long-term use, is the first new treatment for fibromyalgia in more than 15 years.
The broader coverage through group purchasing organizations and Medicaid enhances patient access to a treatment option for a condition that affects millions. Fibromyalgia is characterized by widespread musculoskeletal pain, fatigue, and other symptoms, and the introduction of TONMYA addresses a significant unmet medical need. The company, a fully-integrated, commercial-stage biotechnology firm focused on central nervous system (CNS) and immunology treatments, is building its CNS commercial infrastructure to support marketed products, including its acute migraine products Zembrace SymTouch and Tosymra.
Tonix is also advancing clinical trials for TONMYA in major depressive disorder and acute stress disorder, as well as developing a pipeline of CNS and immunology programs. These include TNX-2900 for Prader-Willi syndrome, TNX-4800 for Lyme disease prophylaxis, and TNX-1500 for prevention of kidney transplant rejection. The company’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established.
The expansion of TONMYA coverage is significant for patients, healthcare providers, and the pharmaceutical industry. For patients, increased access means more options for managing fibromyalgia, a condition often treated with off-label medications. For healthcare providers, the availability of a non-opioid analgesic supports safer prescribing practices in light of the opioid epidemic. For the industry, Tonix’s success demonstrates the viability of developing and commercializing treatments for conditions with high unmet need.
Investors may view the expanded coverage as a positive indicator of market adoption and potential revenue growth. The company’s ability to secure agreements with major purchasing organizations and Medicaid suggests a favorable market reception. However, the company continues to face challenges, including ongoing discussions with Medicare and the need for further clinical development of its pipeline candidates.
For more information, visit the company's newsroom at https://ibn.fm/TNXP.
